Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Official Title

Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer


This is a pilot study of neoadjuvant 'immunoradiation' (durvalumab or durvalumab plus tremelimumab) administered every 4 weeks for 2 doses, concurrently with standard thoracic radiation (RT) (45Gy in 25 fractions), with one dose of immunotherapy alone delivered in the pre-surgical window, prior to surgical resection, for patients with stage IIIA NSCLC that is deemed resectable with a lobectomy by a thoracic surgeon. If preliminary safety of the durvalumab/thoracic RT combination is established, a second cohort investigating the combination of durvalumab/tremelimumab/thoracic RT prior to surgical resection will be opened. After surgical resection, patients may receive standard adjuvant chemotherapy, as deemed appropriate by the treating investigator.

Trial Description

Primary Outcome:

  • Toxicities as measured by number of participants experiencing adverse events
  • Feasibility of Preoperative Immunoradiation
Secondary Outcome:
  • Surgical Morbidity and Mortality
  • Percentage of Participants with Pathologic Response
  • Percentage of Participants with Radiologic Response
  • Duration of Response as measured by recurrence-free survival
  • Overall Survival

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society